Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Assessing the Effects of a Buckwheat Beverage on Postprandial Glucose Metabolism on Healthy and T2D Individuals (BUCKFOOD)

17 de abril de 2019 atualizado por: University of Aberdeen

Buckwheat is a unique crop because is naturally rich in compounds that have shown beneficial effects on glucose metabolism.

A constant high glucose level in blood after meal consumption is an independent risk factor for cardiovascular complications and death. In order to prevent Type 2 Diabetes Mellitus (T2D) and/or its complications it is important to have a strict control of the blood glucose levels after a meal. There are known therapies for the control of the high glucose blood levels such as agents that act on intestinal digestion of carbohydrates and therapeutic agents that mimic the insulin response after a meal. The combination of these type of agents was commonly prescribed in the treatment of T2D.

The aim of the study is to assess the effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet.

Visão geral do estudo

Status

Desconhecido

Intervenção / Tratamento

Descrição detalhada

The ability of the buckwheat beverage to modulate postprandial sugar metabolism will be tested in a dietary study in healthy volunteers and people with T2D. Three groups will be recruited; healthy volunteers, individuals with T2D controlled by medication and individuals with T2D controlled by diet and lifestyle only.

For the human volunteers who have T2D controlled by medication, there will be targeted those who have been prescribed metformin only.

The volunteers will visit the Human Nutrition Unit (HNU) three times (a screening visit and two study visits) during the course of the study.

A minimum of two weeks between the study visits will be allowed.

Screening visit:

Once the consent form has been signed, the volunteers taking part in the study will answer a specific health questionnaire and have their blood sugar level measured. The HbA1c (glycated haemoglobin) will be measured using the AS-100 (finger spot blood). We will follow the NHS guideline to establish the values for HbA1c. A normal HbA1c target is below 48 mmol/mol (or 6.5%).

In addition, for the volunteers with T2D, a consultant from the study research team will access the medical records to ensure their eligibility for the study. Permission will be obtained from the volunteers for this via the study consent form.

Dietary study test meal and control meal:

The test meal The buckwheat beverage is prepared from sprouted buckwheat flour without adding any extra sugar, spices or aromas. The test meal contains 100 g of the buckwheat beverage and 75 g glucose dissolved in 300 mL water followed by 100 mL water.

The control meal The control meal will be a standard OGT test containing 75 g glucose dissolved in 300 mL of water followed by 100 mL water.

Both meals will be advised to be consumed within 5 minutes. The T2D volunteers which are on metformin will be advised to take their medication as usual. We will record the dose and time when the metformin will be taken by the volunteers.

Dietary study visits:

Following recruitment, screening and consent, the three groups of volunteers will start the study by random allocation to one of the test meals. On the study day, the volunteers will be advised to come to the HNU in the morning after an overnight fasting (10 h). A cannula will be inserted into the volunteers' arm and baseline blood will be collected. The cannulation and blood sampling will be performed by trained phlebotomists. Additionally a baseline urine sample will be collected. The urine sample either will be brought in by the volunteers in the morning or produced in HNU before the test meals. The volunteers will be served the control and test meal (depending on allocation) and advised that it is to be consumed within five minutes. Volunteers which are on metformin will be asked to take their medication as usual.

For each study visit, blood will be collected at 0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180 and 300 min. The blood will be collected in 4 mL lithium heparin tubes and 4 mL glucose (fluoride oxalate) tubes at each time point. A volume of 96 mL of blood will be collected at each study visit. Additionally a volume of 5 μL blood will be collected for each time point in order to instantly measure the glucose levels. At least two samples will be collected at t=0 in order to obtain a good baseline value.

The movements of the volunteers will be restricted to minimum for the entire blood collection period. They will be asked to stay resting and comfortable position and relaxed for the entire (300 min) sampling period and to not leave the HNU.

After five hours, once all the blood samples have been collected the cannula will be extracted from the volunteer's arm and lunch will be provided.

Tipo de estudo

Intervencional

Inscrição (Antecipado)

54

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Aberdeen, Reino Unido, AB 25 2ZD
        • Recrutamento
        • Rowett Institute, University of Aberdeen
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Healthy and T2D (controlled by diet and lifestyle or metformin) volunteers; Age 18+; males and females.

Exclusion Criteria:

For the healthy group:

  • taking prescribed medication
  • HbA1c above 48mmol/mol (or 6.5%)
  • pregnant or breastfeeding
  • blood donation in the last three months
  • unable to give written informed consent
  • eating disorders such as anorexia, bulimia, binge eating or night eating syndrome.
  • significant health issue
  • taking vitamin or mineral supplements (unless they agree to discontinue supplementation 2 weeks or more before the start of the study)
  • Food allergies/intolerances

For the T2D groups:

  • T2D controlled by medication other than metformin
  • pregnant or breastfeeding
  • blood donation in the last three months
  • unable to give written informed consent
  • eating disorders such as anorexia, bulimia, binge eating or night eating syndrome.
  • any other significant health issue other than T2D
  • taking vitamin or mineral supplements (unless they agree to discontinue supplementation 2 weeks before the start of the study)
  • food allergies/intolerances

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Control meal
The control meal will be a standard OGT test containing 75 g glucose dissolved in 300 mL of water followed by 100 mL water.
The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.
Comparador Ativo: The test meal
The test meal contains 100 g of the buckwheat beverage and 75 g glucose dissolved in 300 mL water followed by 100 mL water.
The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
post prandial blood glucose (recording cmax)
Prazo: five hours
Postprandial blood glucose levels after acute consumption of a buckwheat beverage, recording the maximum blood glucose concentration (c max) over the baseline after the consumption of a buckwheat beverage.
five hours
AUC for postprandial glucose
Prazo: five hours
Area under the curve described by the postprandial glucose level during five hours time
five hours

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
post prandial blood insulin in blood ( including AUC)
Prazo: five hours
Post prandial blood insulin levels after acute consumption of a buckwheat beverage. AUC (area under curve) for insulin for five hour interval.
five hours
Buckwheat beverage key bioactives bioavailability and metabolism.
Prazo: five hours
Plasma concentration of key bioactives (inositols and fagomines)
five hours
Urine ratio of myo and D-chiro inositol
Prazo: 0, 3 and 5 hours
Urine ratio of myo and D-chiro inositol after the consumption of a buckwheat beverage.
0, 3 and 5 hours
Urine glucose concentration
Prazo: 0, 3 and 5 hours
Glucose concentration in urine after the consumption of a buckwheat beverage.
0, 3 and 5 hours

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

7 de março de 2019

Conclusão Primária (Antecipado)

7 de setembro de 2020

Conclusão do estudo (Antecipado)

31 de março de 2021

Datas de inscrição no estudo

Enviado pela primeira vez

3 de abril de 2019

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de abril de 2019

Primeira postagem (Real)

22 de abril de 2019

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de abril de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de abril de 2019

Última verificação

1 de abril de 2019

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

Não

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Dietary Intervention

3
Se inscrever